Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICE and BEAM Chemotherapy with Stem Cell Transplant in Older Patients with Refractory/Relapsed NHL
NCT00002982Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 1997
- Primary completion
- Oct 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ifosfamide, carboplatin, etoposide, carmustine, cytarabine and 1 more in non-Hodgkin lymphoma (NHL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Treatment-related toxicity. Started Jan 1997; status: completed.
02
Drugs
ifosfamidecarboplatinetoposidecarmustinecytarabine
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00002982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002982.